Catalyst Wire Dossier Catalyst Wire Dossier

Dolutegravir plus lamivudine

dolutegravir; lamivudine · ViiV Healthcare
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Dolutegravir plus lamivudine, covering 2020-06-02 to 2020-06-02. Get the full timeline:

Most recent: Clinical Trial Update: Switch Study to Evaluate Dolutegravir Plus Lamivudine in Virologically Suppressed Human Immunodeficiency Virus Type 1 Positive Adults (TANGO) [Phase 3]

See pricing